The Blood Microbiome Predicts Acute Graft-Versus-Host Disease after Stem Cell Transplantation
Lily Blair, Kate A. Markey(Cornell University), Ying Taur(Memorial Sloan Kettering Cancer Center), Jonathan U. Peled(Memorial Sloan Kettering Cancer Center), Sivan Bercovici(Fresenius Medical Care (United States)), Paul A. Giardina(Memorial Sloan Kettering Cancer Center), Desiree Hollemon, David K. Hong(Unknown), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Ann E. Slingerland(Cornell University), John Slingerland(Cornell University), Marcel R.M. van den Brink(City Of Hope National Medical Center), Carine Ho, Asim A. Ahmed
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k